公開日期 | 標題 | 作者 | 來源出版物 | scopus | WOS | 全文 |
---|---|---|---|---|---|---|
2018 | Afatinib as First-line Treatment of Older Patients With EGFR Mutation-Positive Non-Small-Cell Lung Cancer: Subgroup Analyses of the LUX-Lung 3, LUX-Lung 6, and LUX-Lung 7 Trials | Wu Y.-L; Sequist L.V; Tan E.-H; Geater S.L; Orlov S; Zhang L; Lee K.H; Tsai C.-M; Kato T; Barrios C.H; Schuler M; Hirsh V; Yamamoto N; O'Byrne K; Boyer M; Mok T; Peil B; Märten A; Chih-Hsin CHIH-HSIN YANG ; Paz-Ares L; Park K. | Clinical Lung Cancer | 53 | 41 | |
2015 | Afatinib versus cisplatin-based chemotherapy for EGFR mutation-positive lung adenocarcinoma (LUX-Lung 3 and LUX-Lung 6): Analysis of overall survival data from two randomised, phase 3 trials | CHIH-HSIN YANG ; Wu Y.-L; Schuler M; Sebastian M; Popat S; Yamamoto N; Zhou C; Hu C.-P; O'Byrne K; Feng J; Lu S; Huang Y; Geater S.L; Lee K.Y; Tsai C.-M; Gorbunova V; Hirsh V; Bennouna J; Orlov S; Mok T; Boyer M; Su W.-C; Lee K.H; Kato T; Massey D; Shahidi M; Zazulina V; Sequist L.V. | The Lancet Oncology | 1318 | 1236 | |
2016 | Afatinib versus gefitinib as first-line treatment of patients with EGFR mutation-positive non-small-cell lung cancer (LUX-Lung 7): A phase 2B, open-label, randomised controlled trial | Park K; Tan E.-H; O'Byrne K; Zhang L; Boyer M; Mok T; Hirsh V; CHIH-HSIN YANG ; Lee K.H; Lu S; Shi Y; Kim S.-W; Laskin J; Kim D.-W; Arvis C.D; Kölbeck K; Laurie S.A; Tsai C.-M; Shahidi M; Kim M; Massey D; Zazulina V; Paz-Ares L. | The Lancet Oncology | 905 | 827 | |
2018 | Clinical activity of ASP8273 in Asian patients with non-small-cell lung cancer with EGFR activating and T790M mutations | Murakami H; Nokihara H; Hayashi H; Seto T; Park K; Azuma K; Tsai C.-M; CHIH-HSIN YANG ; Nishio M; Kim S.-W; Kiura K; Inoue A; Takeda K; Kang J.-H; Nakagawa T; Takeda K; Akazawa R; Kaneko Y; Shimazaki M; Morita S; Fukuoka M; Nakagawa K. | Cancer Science | 11 | 10 | |
2018 | CNS response to osimertinib in patients with T790M-positive advanced NSCLC: Pooled data from two phase II trials | Goss G; Tsai C.-M; Shepherd F.A; Ahn M.-J; Bazhenova L; Crinò L; de Marinis F; Felip E; Morabito A; Hodge R; Cantarini M; Johnson M; Mitsudomi T; Jänne P.A; CHIH-HSIN YANG | Annals of Oncology | 183 | 164 | |
2021 | Comparative Study of Li-CO2and Na-CO2Batteries with Ru@CNT as a Cathode Catalyst | Thoka S; Tsai C.-M; Tong Z; Jena A; Wang F.-M; Hsu C.-C; Chang H; Hu S.-F; Liu R.-S.; RU-SHI LIU | ACS Applied Materials and Interfaces | 34 | 31 | |
2016 | First-Line Pemetrexed Plus Cisplatin Followed by Gefitinib Maintenance Therapy Versus Gefitinib Monotherapy in East Asian Never-Smoker Patients with Locally Advanced or Metastatic Nonsquamous Non-Small-cell Lung Cancer: Quality of Life Results from a Randomized Phase III Trial | Boye M; Wang X; Srimuninnimit V; Kang J.H; Tsai C.-M; Orlando M; Puri T; Kim J.S; Rajan N; CHIH-HSIN YANG | Clinical Lung Cancer | 12 | 13 | |
2016 | Gefitinib maintenance therapy versus gefitinib monotherapy in east asian never-smoker patients with locally advanced or metastatic nonsquamous non-small cell lung cancer: Final overall survival results from a randomized phase 3 study | CHIH-HSIN YANG ; Srimuninnimit V; Ahn M.-J; CHIA-CHI LIN ; Kim S.-W; Tsai C.-M; Mok T; Orlando M; Puri T; Wang X; Park K. | Journal of Thoracic Oncology | 22 | 20 | |
2013 | Impact of EGFR inhibitor in non-small cell lung cancer on progression-free and overall survival: A meta-analysis | Lee C.K; Brown C; Gralla R.J; Hirsh V; Thongprasert S; Tsai C.-M; Tan E.H; Ho J.C.-M; Chu D.T; Zaatar A; Osorio Sanchez J.A; Vu V.V; Au J.S.K; Inoue A; Lee S.M; Gebski V; CHIH-HSIN YANG | Journal of the National Cancer Institute | 455 | 409 | |
2019 | Osimertinib in patients with T790M mutation-positive, advanced non–small cell lung cancer: Long-term follow-up from a pooled analysis of 2 phase 2 studies | Ahn M.-J; Tsai C.-M; Shepherd F.A; Bazhenova L; Sequist L.V; Hida T; CHIH-HSIN YANG ; Ramalingam S.S; Mitsudomi T; Jnne P.A; Mann H; Cantarini M; Goss G. | Cancer | 120 | 111 | |
2013 | Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations | Sequist L.V; CHIH-HSIN YANG ; Yamamoto N; O'Byrne K; Hirsh V; Mok T; Geater S.L; Orlov S; Tsai C.-M; Boyer M; Su W.-C; Bennouna J; Kato T; Gorbunova V; Lee K.H; Shah R; Massey D; Zazulina V; Shahidi M; Schuler M. | Journal of Clinical Oncology | 2727 | 2366 | |
2013 | Second-line pemetrexed treatment in Taiwanese patients with advanced nonsmall cell lung cancer: An open-label single-arm study | Chang G.-C; Tsai C.-M; Hsia T.-C; CHIH-HSIN YANG ; Abdulnabi R; Blair J.M; Linn C. | Journal of the Formosan Medical Association | 1 | 1 |